| Browse All

Advanced Biomed Inc. (ADVB)

Healthcare | Diagnostics & Research | New York, United States | NasdaqCM
5.00 USD +0.20 (4.167%) ⇧ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★☆☆☆☆
Hot Take | April 18, 2026, 11:54 p.m. EDT

Despite a recent volatile price spike (approx. 39% gain in one week), the stock displays severe bearish divergence: it is trading at 60% of its 200-day moving average, has exhausted its two most recent months of trading volume, and a quantitative model predicts a -12.6% move over the next 45 days due to high tail risk and non-normal distribution stability issues.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.180931
AutoARIMA0.199888
AutoETS0.237154
MSTL0.242043

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 33%
H-stat 7.97
Ljung-Box p 0.000
Jarque-Bera p 0.021
Excess Kurtosis 0.19
Attribute Value
Sector Healthcare
Debt to Equity Ratio 7.538
Market Cap 6,822,680
Trailing P/E 1.42
Website https://www.advanbiomed.com

Info Dump

Attribute Value
52 Week Change -0.8587571
Address1 122 East 42nd Street
Address2 18th Floor
All Time High 82.0
All Time Low 3.61
Ask 6.06
Ask Size 2
Average Daily Volume10 Day 1,581,120
Average Daily Volume3 Month 490,126
Average Volume 490,126
Average Volume10Days 1,581,120
Bid 3.53
Bid Size 2
Book Value 8.763
City New York
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 5.0
Current Ratio 8.561
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 5.095
Day Low 4.502
Debt To Equity 7.538
Display Name Advanced Biomed
Earnings Timestamp End 1,747,339,200
Earnings Timestamp Start 1,747,339,200
Ebitda -2,971,404
Ebitda Margins 0.0
Enterprise To Ebitda -1.185
Enterprise Value 3,520,026
Eps Trailing Twelve Months 3.52
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.791
Fifty Day Average Change 0.20900011
Fifty Day Average Change Percent 0.043623485
Fifty Two Week Change Percent -85.87571
Fifty Two Week High 48.8
Fifty Two Week High Change -43.8
Fifty Two Week High Change Percent -0.897541
Fifty Two Week Low 3.61
Fifty Two Week Low Change 1.3900001
Fifty Two Week Low Change Percent 0.3850416
Fifty Two Week Range 3.61 - 48.8
Financial Currency USD
First Trade Date Milliseconds 1,741,271,400,000
Float Shares 368,843
Free Cashflow -10,735,010
Full Exchange Name NasdaqCM
Full Time Employees 31
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.5505
Held Percent Institutions 0.00162
Implied Shares Outstanding 1,364,536
Industry Diagnostics & Research
Industry Disp Diagnostics & Research
Industry Key diagnostics-research
Ipo Expected Date 2,025-03-06
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,751,241,600
Last Split Date 1,771,545,600
Last Split Factor 1:20
Long Business Summary Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Long Name Advanced Biomed Inc.
Market us_market
Market Cap 6,822,680
Market State PRE
Max Age 86,400
Message Board Id finmb_1821058753
Most Recent Quarter 1,767,139,200
Net Income To Common 4,049,137
Next Fiscal Year End 1,782,777,600
Non Diluted Market Cap 6,822,680
Open 4.74
Operating Cashflow -6,077,434
Operating Margins 0.0
Payout Ratio 0.0
Pre Market Change 0.25259972
Pre Market Change Percent 5.3320327
Pre Market Price 4.99
Pre Market Time 1,776,758,407
Previous Close 4.8
Price Hint 4
Price To Book 0.5705809
Profit Margins 0.0
Quick Ratio 2.149
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.19999981
Regular Market Change Percent 4.1666627
Regular Market Day High 5.095
Regular Market Day Low 4.502
Regular Market Day Range 4.502 - 5.095
Regular Market Open 4.74
Regular Market Previous Close 4.8
Regular Market Price 5.0
Regular Market Time 1,776,715,200
Regular Market Volume 133,675
Return On Assets -0.26904
Return On Equity 0.80176
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,364,536
Shares Percent Shares Out 0.019199999
Shares Short 26,190
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 22,721
Short Name Advanced Biomed Inc.
Short Percent Of Float 0.0352
Short Ratio 0.07
Source Interval 15
State NY
Symbol ADVB
Total Cash 2,604,666
Total Cash Per Share 2.407
Total Debt 714,692
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 3.52
Trailing P E 1.4204545
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.79805
Two Hundred Day Average Change -2.79805
Two Hundred Day Average Change Percent -0.35881406
Type Disp Equity
Volume 133,675
Website https://www.advanbiomed.com
Zip 10,168